8-K: CareDx Reports Strong Q4 and Full Year 2024 Results, Revenue Up 19% to $334 Million

CareDx announces a 19% increase in full year 2024 revenue, reaching $334 million, and anticipates further growth in 2025.

Summary

• CareDx reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year 2024 revenue grew by 19% to $333.8 million.
• The company expects full year 2025 revenue to be between $365 million and $375 million.
• Fourth quarter revenue increased by 32% year-over-year to $86.6 million.
• Testing services revenue for the fourth quarter increased by 37% year-over-year to $63.8 million, with testing services volume up 14% year-over-year to approximately 45,500.
• GAAP net income for the fourth quarter was $87.7 million, compared to a net loss of $118.1 million in the same period of 2023.
• Adjusted EBITDA for the fourth quarter was $9.8 million, a significant improvement from the $10.3 million loss in the fourth quarter of 2023.
• For the full year 2024, GAAP net income was $52.5 million, compared to a net loss of $190.3 million in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $261 million as of December 31, 2024, with no debt.
• In February 2025, the Board of Directors authorized a common stock repurchase program of up to $50 million over 24 months.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, revenue growth, and improved profitability. The stock repurchase program further boosts investor confidence.

Positives

• Significant revenue growth in both Q4 and full year 2024.
• Substantial improvement in net income and adjusted EBITDA compared to the previous year.
• Strong cash position with no debt.
• Stock repurchase program indicates confidence in the company's future prospects.
• Testing services volume continues to grow sequentially.
• Successful publication of studies validating the accuracy of AlloSeq cfDNA in detecting organ transplant rejection.
• The company submitted the first manuscript of the Kidney Outcomes Allograft Rejection (KOAR) study for publication.

Risks

• The forward-looking statements are subject to numerous risks and uncertainties, including general economic and market factors.
• Global economic and marketplace uncertainties could impact the company's ability to achieve its financial and operational goals.
• The company's filings with the SEC detail other risks that could cause actual results to differ materially from those projected.

Future Outlook

CareDx expects full year 2025 revenue to be in the range of $365 million to $375 million and adjusted EBITDA to be in the range of $29 million to $33 million.

Management Comments

• 2024 was a transformative year for CareDx, positioning the company for long-term profitable growth, said John W. Hanna, CareDx President and CEO.
• We look forward to another year of strong performance in 2025, driven by our focus on testing services volume growth, expansion of payer coverage, and operational excellence as we scale our business.

Industry Context

CareDx is a leading precision medicine solutions company focused on transplant patients, and these results demonstrate its continued growth and market leadership in genomics-based information for transplant patients.

Comparison to Industry Standards

• It is difficult to compare CareDx directly to other companies due to its unique focus on transplant diagnostics.
• However, companies like Natera and Exact Sciences operate in the broader molecular diagnostics market and can be used as benchmarks for growth and profitability.
• CareDx's 19% revenue growth is competitive with other high-growth diagnostics companies.
• The company's focus on adjusted EBITDA profitability is a positive sign, as many diagnostics companies struggle to achieve profitability at scale.

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and stock repurchase program.
• Employees may benefit from the company's growth and profitability.
• Transplant patients and caregivers will continue to benefit from CareDx's innovative diagnostic solutions.

Key Dates